Recombinant Human Transmembrane protease serine 2(TMPRSS2),partial

1. A potential novel function of TMPRSS2-ERG as a major regulator of IGF1R gene expression. PMID: 27285981
2. Study shows that T2E fusion transcripts are associated with higher levels of AMACR mRNA in patients with atypical small acinar proliferation (ASAP) which represents an indicator of risk for prostate cancer in patients with ASAP. PMID: 29277318
3. TMPRSS2-ERG may have a role in progression of prostate neoplasms and in alteration of the metabolic profile PMID: 27276682
4. We propose that epigenetic events are a significant and alternative driver of aggressive disease in TMPRSS2-ERG fusion-negative prostate cancer. PMID: 27814612
5. Meta-analysis showed the prevalence of TMPRSS2:ERG fusions in prostate cancer to be highest in men of European descent (49%), followed by Asians (27%) and then African (25%) descent. PMID: 28633309
6. Data show that tumors displaying TMPRSS2-ERG fusions that retained interstitial genes were less likely to be associated with biochemical recurrence PMID: 29127096
7. We demonstrate a role for inflammation-induced oxidative stress in the formation of DNA breaks leading to recurrent TMPRSS2-ERG gene fusions. The transcriptional status and epigenetic features of the target genes influence this effect. PMID: 27926866
8. NOTCH pathway inhibition antagonizes the growth and invasion of transmembrane protease serine 2 (TMPRSS2)-transforming protein ERG (ERG) (T2E) -positive prostate cancer cells. PMID: 28783165
9. The TMPRSS2-ERG gene fusion is the most frequently observed genetic aberration in prostate cancer. PMID: 28845585
10. Study provide evidence that PTEN deletion and TMPRSS2-ERG gene fusion were mutually exclusive in patients with prostate neoplasm. TMPRSS2-ERG gene fusion was rare compared to peripheral zone tumors and to PTEN inactivation in T1a transition zone tumors. PMID: 27500376
11. miR-204 upregulates androgen receptor (AR ) and downregulates TMPRSS2/ERG through direct regulation of their promoter methylation and set of transcription factors during AR cancer-related reprogramming. PMID: 28050800
12. differential expression of TMPRSS2:ERG in urine exosomes in prostate cancer and controls PMID: 27144529
13. The present study established evidence for the first two common PrCa risk variants differentially associated with TMPRSS2:ERG fusion status. TMPRSS2:ERG phenotyping of larger studies is required to determine comprehensive sets of variants with subtype-specific roles in prostate cancer. PMID: 27798103
14. Human coronavirus 229E presumably evolved to bypass the endosome by entering the cell via TMPRSS2. PMID: 27733646
15. Studies indicate that TMPRSS2-ERG fusion gene positive prostate cancers cells rewire intracellular signaling cascades and modulate gene and protein network. PMID: 28364793
16. TMPRSS2-ERG role in prostate cancer invasiveness and regulation of MMP-9 and plexin B1. PMID: 28004109
17. Our results indicate that it is possible to predict pT3 stage at final histology from TMPRSS2:ERG gene fusion at initial core needle biopsy. FISH determination of TMPRSS2:ERG gene fusion may be particularly useful for patients scheduled to undergo a radical prostatectomy in order to improve oncological and functional results PMID: 27377958
18. Data show there was a good agreement of transcriptional regulator ERG protein (ERG) immunostaining with the presence of TMPRSS2:ERG fusion protein. PMID: 27320318
19. A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening. PMID: 27630329
20. Studies showed that urinary TMPRSS2:ERG transcripts seem to be indicative of Prostate cancer aggressiveness upon biopsy. [review] PMID: 26774207
21. Aspirin was associated with a significant reduction in the relative risk of TMPRSS2:ERG (T2E )fusion positive, but not T2E negative PMID: 26503111
22. the type II transmembrane serine protease TMPRSS2 was able to activate hemagglutinin for cell entry indicating that bat influenza A virus can utilize human proteases for hemagglutinin activation. PMID: 27028521
23. The relatively low rate of ERG-positive prostatic intraepithelial neoplasia counts in favor of the limited role of chimeric transcript TMPRSS2/ERG in the differential diagnosis of prostatic intraepithelial neoplasia PMID: 26978019
24. TMPRSS2 isoform 1 is expressed in viral target cells. PMID: 26379044
25. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition PMID: 26026052
26. The potential for TMPRSS2:ERG gene fusion, detected by IHC, to modify the role of PTEN loss in lethal progression of prostate cancer. PMID: 26615022
27. Results indicate that PTEN loss occurs in cooperation with TMPRSS2-ERG fusion in prostate cancer and the majority of the samples harbor TMPRSS2-ERG fusion as well as PTEN gene deletion. PMID: 26424596
28. Elucidation of ERG regulation of ABEs in castration-resistant prostate cancer (CRPC) may help to stratify TMPRSS2-ERG fusion-positive prostate cancer patients in the clinic for anti-androgen receptor-driven therapies. PMID: 25754347
29. these data show that the androgen-driven events causing TMPRSS2-ERG fusions and other rearrangements of androgen-dependent genes in prostate epithelial cells of young patients preferentially lead to low-grade (and not high-grade) prostate cancer. PMID: 25015038
30. TMPRSS2-ERG fusion gene transcript was found in 63, 55 and 73% of the prostate cancer cases on urine alone, biopsy rinse material alone and paired samples, respectively. PMID: 24997128
31. Genetic inhibition of TMPRSS2-ERG junction oncogene in prostate cancer by means of siRNA has strong antineoplastic effect in a mouse model and in vitro. PMID: 25933120
32. Data showed that TMPRSS2 expression is not only dramatically increased in the primary cancers of patients but TMPRSS2 immunopositivity is also directly correlated with cancer pain severity in these patients. PMID: 25734995
33. High AR gene copy number emerges during the development of Small cell carcinoma of the prostate, often in association with TMPRSS2-ERG rearrangement. PMID: 24777847
34. Both IHC and qRT-PCR are useful tools in detecting TMPRSS2:ERG fusions. PMID: 25007891
35. Membrane bound meprin Beta is activated by transmembrane serine protease matriptase-2 at the cell surface. PMID: 26251449
36. Data indicate that inhibition of transcriptional regulator ERG protein expression in transmembrane protease serine 2 protein (TMPRSS2):ERG-positive prostate cancer cells increased neuroendocrine cell gene expression. PMID: 25263440
37. TMPRSS2 promotes the growth, invasion, and metastasis of prostate cancer cells via matriptase activation and extracellular matrix disruption. PMID: 26018085
38. Analysis of prostate cancer tissues showed that the presence of a TMPRSS2-ERG rearrangement was highly correlated with lower levels of NKX3.1 expression consistent with the role of NKX3.1 as a suppressor of the pathogenic gene rearrangement. PMID: 25977336
39. The TMPRSS2 Met160Val polymorphism is a genetic risk factor for sporadic prostate cancer in a Japanese population. PMID: 25040002
40. The expression levels of the TMPRSS2-ERG fusion is related to a more aggressive phenotype, have an effect on prognosis and could be molecular markers of progression for prostate cancer. PMID: 25939480
41. Results provide suggestive evidence that men with TMPRSS2:ERG positive tumors may have longer prostate cancer survival after ADT. PMID: 25728532
42. recent and maximum BMI are inversely associated with the odds of developing T2E-positive prostate cancer, but no associations were observed for T2E-negative prostate canc PMID: 25852077
43. TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. PMID: 24186205
44. activates hepatitis C virus infection at the postbinding and entry stage PMID: 25203900
45. results demonstrate the ability of confocal microscopy and FISH to identify the cell-to-cell differences in common gene fusions such as TMPRSS2-ERG that may arise independently within the same tumor focus PMID: 25175909
46. The effect of TMPRSS2/ERG gene fusions had differing effects on radiosensitivity and chemosensitivity depending on cell line and fusion type. PMID: 21394739
47. These findings indicate that TMPRSS2-ERG may or may not lead to prostate cancer development PMID: 24961351
48. Report prognostic value of tissue/urinary TMPRSS2-ERG levels in prostate neoplasms. PMID: 24072184
49. concurrent in situ detection of gene expression, point mutations, and gene fusions of the prostate cancer relevant targets TMPRSS2-ERG PMID: 24931216
50. TMPRSS2:ERG gene fusion synergizes with the VDR to induce CYP24A1 expression-limiting VDR signaling. PMID: 24926821
51. Prostate cancer specific PCA3 and TMPRSS2-ERG mRNAs are detected in the mononuclear fraction of a castration-resistant prostate cancer patient cohort PMID: 25043536
52. Our findings suggested that AR CAG repeats are not associated with TMPRSS2:ETS formation in prostate cancer. PMID: 24824408
53. These observations imply that the frequently noted loss-of-function of NKX3.1 cooperates with the activation of TMPRSS2-ERG fusions in prostate tumorigenesis. PMID: 24418414
54. Our observations indicate a tight link of NY-ESO-1 expression to ERG activation PMID: 24789172
55. The presence of single nucleotide polymorphism might have implications on the expression and/or formation levels of TMPRSS2 fusions, because both have been shown to be influenced by androgens. PMID: 24109594
56. Patients with ERG expression were more likely to develop PCa, with 27 (53%) of 51 ERG-positive and 143 (35%) of 410 ERG-negative patients experiencing progression to PCa. PMID: 24297949
57. ERG expression correlates with occurrence of TMPRSS2-ERG fusion and with androgen receptor-driven malignant transformation. PMID: 24195515
58. TMPRSS2-ERG rearrangement occurs in dominant transition zone (TZ) and anterior peripheral zone prostate cancers, with all rearranged TZ cancers in this cohort showing deletion. PMID: 23701505
59. Results suggest that obesity is linked with poorer prostate cancer prognosis primarily in men with tumors harboring the gene fusion TMPRSS2:ERG. PMID: 24292212
60. Data indicate combining serum PSA, PCA3, and TMPRSS2:ERG in a multivariable algorithm optimized for clinical utility improved cancer prediction. PMID: 21600800
61. Coronavirus infection is mediated by the host transmembrane TMPRSS2. PMID: 24027332
62. characterization of native ERG and Tmprss2:ERG variants reveals that their different oncogenic potential is affected by the status of the Ets domain and the configuration of the 5' UTR region PMID: 23472063
63. Frequent TMPRSS2-ERG rearrangement occurs in prostatic small cell carcinoma as detected by fluorescence in situ hybridization. PMID: 23850495
64. presence and expression of TMPRSS2/ERG in prostate stem cells would provide ERG-driven survival advantages, allowing maintenance of this mutated genotype PMID: 23535644
65. TMPRSS2 and HAT activate HCoV-229E for cathepsin L-independent virus-cell fusion. PMID: 23536651
66. Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements show strong clustering in specific intronic regions in prostate cancer. PMID: 23447416
67. This work uncovers significant global epigenetic alterations in TMPRSS2-ERG gene fusion-negative tumors and provides a mechanistic explanation for the tumor formation process. PMID: 22930729
68. TMPRSS2-ERG fusion accelerates prostatic intraepithelial neoplasia development but not progression to adenocarcinoa. PMID: 22860005
69. Analysis using the four-color FISH assay provides sensitive detection of TMPRSS2 and ERG gene rearrangements in prostate cancer. PMID: 23352841
70. TMPRSS2/ERG gene fusion is found in patients with benign prostatic hyperplasia and normal prostate but is significantly increased in prostate cancer samples. PMID: 22674214
71. The transmembrane protease, serine 2:ets-related gene (TMPRSS2:ERG) gene fusion leads to the overexpression of ERG, an E-twenty six (ETS) family transcription factor, and is the most prevalent genetic lesion in prostate cancer. PMID: 22993300
72. TMPRSS2:ERG, or ERG overexpression, is associated with tumor stage but does not strongly predict recurrence or mortality among men treated with radical prostatectomy. PMID: 22736790
73. TMPRSS2 and HAT are expressed by important influenza and SARS-coronavirus target cells and could thus support viral spread in the human host. PMID: 22558251
74. Downregulation of PSMA in androgen-treated VCaP cells appears partially mediated by TMPRSS2-ERG gene fusion. PMID: 21731703
75. This study demonstrates a close relationship of the TMPRSS2-ERG gene fusion status between primary and metastatic prostate cancer. PMID: 21937078
76. Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression. PMID: 22222211
77. TMPRSS2-ERG fusion was not prognostic for recurrence after retropubic radical prostatectomy for clinically localized prostate cancer, although men with ERG gene copy number gain without fusion were twice more likely to recur. PMID: 21743434
78. Suggest that the oncogenic gene fusion TMPRSS2:ERG does not occur in ovarian cancer relative to prostate cancer. PMID: 22076164
79. Prostate specific TMPRSS2-ERG fusion was found in circulating tumor cells but did not predict for response to abiraterone acetate treatment. PMID: 21802835
80. BR-DIM and CDF inhibited the signal transduction in the AR/TMPRSS2-ERG/Wnt signaling network, leading to the inactivation of Wnt signaling consistent with inhibition of prostate cancer cell invasion PMID: 21680704
81. TMPRSS2-ERG gene fusion was found in prostatic small cell carcinoma and adenocarcinoma, but was absent in bladder small cell carcinoma PMID: 21499238
82. TMPRSS2-ERG fusion gene status and relative 8q gain were assessed by fluorescent in situ hybridization in whole formalin fixed paraffin-embedded biopsies PMID: 21584900
83. Knockdown of TMPRSS2-ERG in VCaP cells resulted in the downregulation of wild-type ERG transcription, whereas stable overexpression of TMPRSS2-ERG in the gene fusion-negative PC3 cells was associated with the upregulation of wild-type ERG transcript PMID: 21676887
84. We found that ERG immunohistochemical expression has a high accuracy for defining the TMPRSS-ERG fusion status. PMID: 21677539
85. The authors show that TMPRSS2 might promote viral spread and pathogenesis by diminishing viral recognition by neutralizing antibodies and by activating SARS S for cell-cell and virus-cell fusion. PMID: 21325420
86. The gene fusions TMPRSS2 and E26 are present in over 50% of patients with prostate cancer. [Review] PMID: 21377967
87. The prevalence and class of TMPRSS2-ERG are significantly different in prostate cancer of Caucasian, African-American, and Japanese patients. PMID: 20878952
88. The recent discovery and subsequent characterization of recurrent gene rearrangements of ETS genes - most frequently ERG - in the majority of prostate cancers is a milestone in translational prostate cancer research. PMID: 20798944
89. TMPRSS2 is responsible for Influenza A HA cleavage in Calu-3 airway cells. PMID: 21123387
90. ACE2 and TMPRSS2 colocalized on cell surfaces and enhanced the cell entry of authentic severe acute respiratory syndrome corona virus. PMID: 21068237
91. we demonstrate that most human prostatic small cell carcinomas carry the TMPRSS2-ERG gene fusion, confirming the involvement of this gene fusion in prostatic SCC. PMID: 21040948
92. Prostate cancer with large cribriform glands revealed rare TMPRSS2-ERG gene fusion PMID: 20800881
93. Data suggest that TMPRSS2, an apical surface serine protease, may have a normal role in male reproduction as a component of prostasomes. PMID: 20382709
94. RNAi-mediated knockdown of TMPRSS2 and TMPRSS4 in Caco-2 cells, which released fully infectious virus without trypsin treatment, markedly reduced the spread of influenza virus, demonstrating that these proteases were responsible for activation of HA. PMID: 20631123
95. There was no association between TMPRSS2:ERG fusion and prognosis in prostate cancer patients primarily treated by endocrine PMID: 20442300
96. This is the first study to report concurrent TMPRSS2 and SLC45A3 rearrangements in the same tumor focus in prostate cancer PMID: 20118910
97. the up-regulation of TMPRSS2 and the down-regulation of KLK11 in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness as well as novel prognostic indicators for prostate cancer. PMID: 19242826
98. A significantly reduced expression of TMPRSS2 was evident in malignant cells harboring TMPRSS2-ERG fusion, but not in prostate cancer cells without TMPRSS2-ERG fusion, further defining these two genetically distinct types of prostate cancer. PMID: 19597533
99. TMPRSS2-ERG T1/E4 fusion-positive tumours had differentially regulated mRNAs observed in multiple studies. PMID: 20068566
100. SMARCD1/BAF60a is an androgen receptor cofactor that modulates TMPRSS2 expression PMID: 19762545

Show More

Hide All

HGNC: 11876

OMIM: 602060

KEGG: hsa:7113

STRING: 9606.ENSP00000381588

UniGene: Hs.439309